An experimental peptide vaccine for lung cancer has doubled the one-year survival rate of patients undergoing treatment, reaching 47% compared to 29% with traditional chemotherapy. #TumoreAlPolmone #InnovazioneMedica #VacciniPeptidici (translated)
www.ilsole24ore.com
Tumore al polmone: primi risultati con vaccino sperimentale, quasi raddoppiata la sopravvivenza
